Target intelligence / Profile preview

Host gut mucosa, immune cells, and resident microbiota

Molecular classification
Other
01

Overview

The host gut mucosa, immune cells, and resident microbiota represent a multi-component biological system known as the gut-immune-microbiota axis, which is essential for maintaining human health and homeostasis (Belkaid & Hand, 2014, Science). The gut mucosa acts as a selective physical and chemical barrier, while the resident microbiota contributes to metabolic processes and the development of the host immune system (Thursby & Juge, 2017, Biochem J). Within this environment, specialized immune cells, such as intraepithelial lymphocytes and Peyer's patch cells, engage in constant cross-talk with microbial signals to distinguish between commensal organisms and pathogens (Hooper et al., 2012, Science). Disruptions in this delicate balance, often termed dysbiosis or barrier dysfunction, are linked to the pathogenesis of inflammatory bowel disease (IBD), metabolic disorders, and systemic autoimmunity (Ni et al., 2017, Nat Rev Gastroenterol Hepatol). Therapeutic strategies targeting this system include the use of probiotics to restore microbial balance, biologics like Vedolizumab to prevent pathological immune cell trafficking, and fecal microbiota transplantation to reset the entire ecosystem (Vancamelbeke & Vermeire, 2017, Ther Adv Gastroenterol).

Other names
Gut-immune-microbiota axisIntestinal mucosal barrier systemGut microbiome-immune interfaceGastrointestinal mucosal ecosystem
02

Mechanism of action

Modulation of microbial composition, enhancement of epithelial barrier integrity, and regulation of mucosal immune cell recruitment and activation.

03

Biological functions

Immune responseMetabolismBarrier functionHomeostasisSignal transduction
04

Disease associations

Inflammatory bowel diseaseIrritable bowel syndromeObesityAutoimmune diseaseInfection
05

Safety considerations

Risk of systemic infection (sepsis)Induced dysbiosisImmunosuppression-related opportunistic infectionsVariable therapeutic response across patient populations
06

Interacting drugs

Vedolizumab

5 more in the full profile.

07

Biomarkers

Fecal calprotectinZonulinShort-chain fatty acids (SCFAs)Microbial diversity index (Alpha/Beta diversity)

Beyond the preview

Go deeper on Host gut mucosa, immune cells, and resident microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host gut mucosa, immune cells, and resident microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call